Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Advanced Merger Partners (AMPI.U)
Anzu Special Acquisition I (ANZU.U)
Nightdragon Acquisition (NDACU)
Supernova Partners Acquisition II (SNII.U)
Dhb Capital (DHBCU)
Orion Acquisition Corp. (OHPAU)
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Live Oak Mobility Acquisition (LOKM.U)
Property Solutions Acquisition II (PSAGU)
Atlantic Coastal Acquisition (ACAHU)
Khosla Ventures Acquisition Co. (KVSA)
TCW Special Purpose Acquisition Corp. (TSPQ.U)
Aurora Acquisition Corp. (AURCU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Roblox Corporation (RBLX)
Coupang, Inc. (CPNG)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Immunocore Holdings Plc (IMCR)

Sector - Healthcare

Price chart

+90.15%
Return from IPO

Company News

IPO Profile

About company

They are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX -- Immune mobilizing monoclonal TCRs Against X disease -- designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging their proprietary, flexible, off-the-shelf ImmTAX platform, they are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, they have dosed over 600 cancer patients with their ImmTAX product candidates, which they believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic. Their clinical programs are being conducted with patients with a broad range of cancers including lung, bladder, gastric, head and neck and ovarian, among others. Their most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Bahija Jallal Brian Di Donato
Employees Founded
291 2007

Contacts

Address: 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom

Telephone: +44 1235 438600

Web page: http://www.immunocore.com

IPO information

Expected Date 2/5/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 8.33
Shares Revised (MM) 9.9
Expected offer amount (MM) $199.92
Realized offer amount(MM) $257.4

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $0
Net Income (Loss) (MM) $-110.86

Voting

What do you think will happen with the IMCR share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Goldman Sachs/ JP Morgan/ Jefferies
CO-Managers
-

Sector: Healthcare

Tweets about $IMCR

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats